Alverno will deploy Ibex's AI software

By LabPulse.com staff writers

August 12, 2021 -- Alverno Laboratories and Ibex Medical Analytics have announced a deal to deploy Ibex's artificial intelligence (AI)-powered Galen software to help pathologists provide diagnosis and care for cancer patients.

Ibex received breakthrough device approval from the U.S. Food and Drug Administration for the Galen software in June. The application is designed to improve the quality of cancer diagnosis, implement real-time quality control, reduce diagnosis time, and boost productivity, the companies said.

Alverno is one of the largest pathology laboratories in the Midwest, managing 32 hospital laboratories. It provides laboratory services to thousands of physician offices.

Unilabs to deploy Ibex's AI platform in Europe
Unilabs signed a deal to implement Ibex Medical Analytics' artificial intelligence (AI) platform in pathology labs across Europe.
Ibex's Galen AI pathology analysis software gets FDA nod
The U.S. Food and Drug Administration (FDA) has designated Ibex Medical Analytics' Galen artificial intelligence (AI) software for pathology image analysis...
Ibex obtains CE Mark for Galen Breast software
Ibex has announced receipt of the CE Mark for its Galen Breast software for use in supporting pathologists in detection of various types of breast cancer.
Philips to partner with Ibex on digital pathology
Royal Philips is partnering with artificial intelligence software developer Ibex Medical Analytics to promote their digital pathology products to hospitals,...
Proscia, Ibex support pathologists in detecting prostate cancer
Proscia and Ibex Medical Analytics are teaming up to support pathologists in detecting prostate cancer through the use of artificial intelligence software.

Copyright © 2021 LabPulse.com

Last Updated ls 8/12/2021 4:36:29 PM